Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | GAA | P10253 | 1/20 | 0.82 |
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11482528 | 0.90 | GAA (0.68) | MAPTGAABRD4MAP1LC3BMEN1 | |
| SCHEMBL20197630 | 0.90 | GAA (0.68) | MAPTGAABRD4MAP1LC3BMEN1 | |
| SCHEMBL562614 | 0.90 | MAPT (1.00) | MAPTGAABRD4MAP1LC3BMEN1 | |
| Formic Acid SCHEMBL27499639 | 0.89 | GAA (0.67) | MAPTGAABRD4MAP1LC3BMEN1 | |
| SCHEMBL29040654 | 0.83 | MAPT (0.84) | MAPTGAABRD4MAP1LC3BMEN1 | |
| SCHEMBL4864740 | 0.81 | GAA (0.63) | MAPTGAABRD4MAPK1POLB | |
| SCHEMBL568689 | 0.81 | GAA (0.63) | MAPTGAABRD4MAPK1POLB | |
| SCHEMBL4878591 | 0.81 | GAA (0.63) | MAPTGAABRD4MAPK1POLB | |
| SCHEMBL13574408 | 0.81 | GAA (0.74) | MAPTGAABRD4MAP1LC3BMEN1 | |
| SCHEMBL16581527 | 0.81 | MAPT (0.57) | MAPTGAABRD4MAP1LC3BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181081-B | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2024-05-17 | — | — | CN | claimed |
| CN-115181081-A | Synthesis method of beta-phenyl-gamma-butyrolactone | 青岛科技大学 | 2022-10-14 | — | — | CN | claimed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | claimed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | claimed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | claimed |
| EP-4663640-A1 | XANTHINE COMPOUND AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024164818-A1 | XANTHINE COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2024-08-15 | — | — | WO | disclosed |
| CN-118459461-A | Xanthine compound and application thereof | 中国科学院上海药物研究所 | 2024-08-09 | — | — | CN | disclosed |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1278728-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-6451819-B2 | PYRROLIDINE-3-YL-SULFANYL, OR SUFONYL OR SUFINYL DERIVATIVES USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | HOFFMANN-LA ROCHE INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001081303-A1 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREAMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-01 | — | — | WO | disclosed |
| US-6160134-A | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines | BRISTOL-MYERS SQUIBB CO. (US) | 2000-12-12 | — | — | US | disclosed |
| US-4035426-A | Diarylcyclobutanes | MEAD JOHNSON & COMPANY (US) | 1977-07-12 | — | — | US | disclosed |
| US-3939196-A | Diarylcyclobutanes | MEAD JOHNSON & COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | SOD1, OAT, SOD3 | MAPT 2241/4885GAA 618/4885BRD4 1452/4885 |
| US-20010047031-A1 | Heterocyclic compounds useful as NMDA receptor selective subtype blockers | GRIN1, GRM1, GRIN2B | MAPT 1856/4885GAA 3423/4885BRD4 1453/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | MAPT 3067/4885GAA 3303/4885BRD4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.